A 50-year-old woman who lived in St Louis, Missouri received a mismatched unrelated bone marrow transplant (BMT) in January 2003 for CML in accelerated phase. She had persistent evidence of disease by cytogenetic analysis but remained relatively stable while on imatinib therapy. She had chronic skin GVHD but was off all immunosuppression at the time of her clinical presentation in August 2004 when she presented with fatigue, fever and shortness of breath. She denied any recent travel history or exposure to insect bites at the time of admission. She had clinical features of cardiac tamponade and rapidly became unstable, requiring intubation and performance of an emergent pericardial window. Bacterial, fungal and mycobacterial cultures from the pericardial fluid were negative and pathology revealed a fibrinous pericarditis. She also developed encephalopathy, seizures and flaccid quadriplegia. An MRI of the brain and cervical spine was performed which revealed no abnormalities. A lumbar puncture was performed and revealed an elevated protein of 162 with 180 nucleated cells. Cytology from the CSF did not reveal any blasts. CSF RT-PCR for WNV was positive at 770 Copies/ml. CSF was also positive for EBV by PCR, but HSV, enterovirus and toxoplasmosis were all negative by PCR analysis.
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Peripheral blood was also sent to detect WNV. Testing for WNV RNA was performed using a commercial realtime reverse transcription PCR assay (Artus Biotech, San Francisco, CA, USA) performed on a Roche Light Cycler. The assay used amplifies a segment of the 5 0 untranslated regions of the viral genome. WNV IgM ELISA was positive on 8/24/04 and 10/19/04 and WNV PCR was 5.1 Â 10 6 Copies/ml from 8/26/04 and 4.0 Â 10 6 Copies/ml from 10/21/04. EBV was also detected in multiple blood samples by PCR with a maximum dilution varying from 1:1000 to 1:10. CMV, enterovirus and HHV-6 were all negative in the serum by PCR analysis.
There have been seven previous case reports of WNV virus infection in BMT patients. [1] [2] [3] [4] In addition to causing encephalitis, WNV infection is associated with a GuillainBarre-like syndrome or a poliomyelitis syndrome. 5 The standard assay for detecting infection with flaviviruses is the IgM ELISA. Molecular diagnosis may also be used for diagnosis although due to the short viremic phase in immunocompetent hosts, nucleic acid amplification assays performed on blood and/or cerebrospinal fluid are frequently negative despite positive serological studies. 6 Of the seven previous case reports, five of the patients had positive IgM ELISA antibody tests for WNV during their clinical course. Despite therapy with IVIG and steroids the patient remained quadriplegic and ventilator dependant at the time of her discharge in November 2004. The patient was readmitted in December 2004 with pneumonia and subsequently developed reaccumulation of pericardial fluid requiring drainage. Repeat testing of both serum and pericardial fluid was negative for WNV by RT-PCR. The patient died in January 2005 after developing sepsis and disseminated HSV infection. In the seven previous case reports in the literature WNV infection was usually associated with a dismal prognosis with five of the seven patients dying shortly after presentation.
We believe that our patient's profound flaccid paralysis was secondary to WNV infection. A notable aspect of this case is the persistent viremia, spanning more than 60 days. To our knowledge, this is the first reported case of persistent WNV viremia, which was most likely secondary to profound and long-standing immunosuppresion following bone marrow transplantation. We suggest that peripheral blood and CSF nucleic acid amplification assays for WNV should be used when the diagnosis of WNV infection is considered in severely immunocompromised patients. When WNV RNA is detected, quantitative assays may be useful for following the clearance of the virus, which may be prolonged in allogeneic BMT recipients. In addition, quantitation of RNA may be useful for evaluating the efficacy of therapeutic interventions. 
